danish pharmaceutical company novo nordisk as nvo announced that introducing its obesity drug wegovy in most european countries will experience delays and the drug is not expected to be available in developing nations for an extended period semaglutide is a peptide sold by novo nordisk under ozempic rybelsus and wegovy for the longterm treatment of type 2 diabetes or obesity chief executive lars fruergaard jorgensen assured stakeholders of their commitment to meet patient expectations over time despite the current challenges in fully meeting demand reuters reported the world health organization also said it is considering adding obesity drugs to its essential medicines list used to guide government purchasing decisions in low and middleincome countries including novo nordisks saxenda wegovy also the british government is set to launch a pilot program to explore the use of new weekly weightloss shots such as novo nordisks wegovy for obese patients outside of specialized services the market launch of the drug remains uncertain novo nordisk has also faced production issues at a contracted manufacturer camilla sylvest the executive vice president of commercial strategy and corporate affairs acknowledged that the launch in other european nations would be slower than initially planned jorgensen highlighted the significant challenges posed by infrastructure limitations such as inadequate cold chain technology in many developing countries making it unlikely for wegovy to become available there for a considerable period price action nvo shares are down 113 at 15946 during the premarket session on the last check tuesday